Adial pharmaceuticals reports first quarter 2023 financial results and provides business update

Conducted meetings with u.s. and select european regulatory agencies received notice of exercise and upfront cash of $0.45 million from advocate for the sale of purnovate assets and business ended 2023 first quarter with cash and cash equivalents of $2.3 million charlottesville, va., may 12, 2023 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw) (“adial” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2023.
ADIL Ratings Summary
ADIL Quant Ranking